DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its second quarter 2025 financial results before the market opens on Wednesday, August 6, 2025, and will host a conference call …
Author: Business Wire
Affirm and New Look Vision Group partner to offer flexible payment options across leading eyewear retailers in Canada
TORONTO–(BUSINESS WIRE)–Affirm (NASDAQ: AFRM), the payment network that empowers consumers and helps merchants drive growth, and New Look Vision Group, a leading North American optical retailer with over 475 stores in the US and Canada, today announc…
Affirm et Groupe Vision New Look s’associent pour offrir des options de paiement flexibles dans les principales lunetteries au Canada
TORONTO–(BUSINESS WIRE)–Affirm (NASDAQ : AFRM), le réseau de paiement qui aide les consommateurs à acheter ce qu’ils souhaitenten toute liberté et soutient la croissance des marchands, et Groupe Vision New Look, un chef de file nord-américain des mag…
Tenpoint Therapeutics Ltd. to Participate in Virtual Presbyopia Panel Hosted by JonesTrading
LONDON & SEATTLE–(BUSINESS WIRE)– #JonesTrading–Henric Bjarke, Chief Executive Officer of Tenpoint, will participate in a Virtual Presbyopia Panel hosted by JonesTrading.
Cloudbreak Pharma Inc.宣布CBT-004治療血管化瞼裂斑病患的第二期臨床試驗取得積極結果
加州爾灣–(BUSINESS WIRE)–(美國商業資訊)– Cloudbreak Pharma Inc.是一家處於臨床階段的眼科公司，致力於開發針對眼表疾病的創新療法。該公司今日宣布，其評估CBT-004眼用溶液治療血管化瞼裂斑及相關結膜充血病患的第二期臨床試驗取得積極頂線結果。 第二期臨床試驗關鍵結果 達到主要終點：獨立閱片中心透過數位成像評估顯示，在第28天，兩種受試濃度的CBT-004相較溶媒對照組，結膜充血均實現具有統計學意義的改善。 起效迅速且療效持久：最高受試濃度的CBT-004…
クラウドブレイク・ファーマ、血管化されたピンゲキュラに罹患した患者を対象としたCBT-004のフェーズ2試験においてポジティブな結果が得られたと発表
カリフォルニア州アーバイン–(BUSINESS WIRE)–（ビジネスワイヤ） — 眼表面疾患に対する革新的な治療法の開発に取り組む臨床段階の眼科医療企業であるクラウドブレイク・ファーマは、血管化されたピンゲキュラおよび関連する結膜充血に罹患した患者を対象とした「CBT-004」点眼薬の有効性を評価する第2相臨床試験において、重要性の高いポジティブな結果が得られたと発表しました。 フェーズ2試験における主な成果 主要エンドポイント（評価項目）を達成：2つのCBT-004の薬物濃度はいずれも、独…
Cloudbreak Pharma Inc.宣布CBT-004治疗血管化睑裂斑患者的2期临床试验取得积极结果
加州尔湾–(BUSINESS WIRE)–(美国商业资讯)– Cloudbreak Pharma Inc.是一家处于临床阶段的眼科公司，致力于开发针对眼表疾病的创新疗法。该公司今日宣布，其评估CBT-004眼用溶液治疗血管化睑裂斑及相关结膜充血患者的2期临床试验取得积极顶线结果。 2期临床试验关键结果 达到主要终点：独立阅片中心通过数字成像评估显示，在第28天，两种受试浓度的CBT-004与溶媒对照组相比，结膜充血均实现具有统计学意义的改善。 起效迅速且疗效持久：最高受试浓度的CBT-004最…
Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 with Regeneron Pharmaceuticals, F. Hoffmann-La Roche, and Bayer Leading Innovations – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Myopic Macular Degeneration Market – A Global and Regional Analysis: Focus on Regional and Country Analysis – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. The global myopic …
Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis and Forecasts 2025-2035 with Regeneron Pharmaceuticals, Kubota Pharmaceutical, and Adverum Biotechnologies Leading – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Wet Age-Related Macular Degeneration (Wet AMD) Market – A Global and Regional Analysis: Focus on Treatment Type, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. Th…
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
IRVINE, Calif.–(BUSINESS WIRE)– #clinicaltrials–Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evalu…
Warby Parker to Announce Second Quarter 2025 Financial Results August 7, 2025
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the second quarter ended June 30, 2025 will be released before mar…
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a …
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
INCHEON, Korea–(BUSINESS WIRE)– #biosimilars–Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis…
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
NASHVILLE–(BUSINESS WIRE)–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclus…
Riassunto: Veranex rivela la prima Innovation CRO (iCRO) di MedTech, ridefinendo la R&S in un mercato a capitale ridotto
RALEIGH, N.C.–(BUSINESS WIRE)–Veranex , un fornitore globale di servizi di sviluppo di prodotti e ricerca a contratto, oggi ha presentato la prima Innovation CRO (iCRO) del settore: una piattaforma che integra sviluppo e ricerca progettata per far pa…
Veranex dévoile la première CRO innovante (iCRO) du secteur des technologies médicales, redéfinissant la R&D dans un marché où les capitaux sont limités
RALEIGH, Caroline du Nord–(BUSINESS WIRE)–Veranex, fournisseur mondial de services de développement de produits et de recherche sous contrat, a présenté aujourd’hui la première CRO innovante (iCRO) du secteur, une plateforme intégrée de développement…
Samenvatting: Veranex onthult eerste Innovation CRO (iCRO) van MedTech en herdefinieert zo R&D in een kapitaalkrappe markt
RALEIGH, N.C.–(BUSINESS WIRE)–Veranex, een wereldwijde leverancier van productontwikkeling en contractonderzoek, introduceerde vandaag de eerste Innovation CRO (iCRO) in de branche: een geïntegreerd ontwikkelings- en onderzoeksplatform dat is ontworp…
Veranex stellt die erste Innovation CRO (iCRO) für den Bereich MedTech vor und definiert damit die Forschung und Entwicklung in einem kapitalarmen Markt neu
RALEIGH, North Carolina–(BUSINESS WIRE)–Veranex, ein globaler Anbieter von Dienstleistungen rund um Produktentwicklung und Auftragsforschung, hat heute die branchenweit erste Innovation CRO (iCRO) vorgestellt. Es handelt sich dabei um eine integriert…
Resumen: Veranex presenta la primera organización de investigación por contrato innovadora (iCRO) del sector de la tecnología médica y redefine la I+D en un mercado con escasez de capital
RALEIGH, Carolina del Norte.–(BUSINESS WIRE)–Veranex, proveedor mundial de servicios de desarrollo de productos e investigación por contrato, ha presentado hoy la primera CRO innovadora del sector (iCRO). Se trata de una plataforma integrada de desar…
Ora Appoints Industry Veteran Bill Sharbaugh as Chairman of the Board of Directors
BOSTON–(BUSINESS WIRE)– #ClinicalResearch–Leading global ophthalmic CRO Ora announces appointment of pharmaceutical industry veteran Bill Sharbaugh as Chairman of Board of Directors.